“…The progression of technology for monitoring neurological signals has substantially expanded the capabilities and understanding of neuroscience over the past decade. − Despite this, the available technologies for such studies largely require bulky, power intensive benchtop systems with complicated operational procedures that require highly trained staff and constant care of the experimental subjects. Real-time, continuous monitoring of in vivo neurotransmitter dynamics presents a key operational capability that is needed to fully elucidate neural pathways involved in several disease archetypes. , Of particular interest among neurotransmitters are catecholamines, particularly dopamine (DA), due to their role in behavioral factors such as motivation and pleasure, , as well as disease archetypes such as addiction, Alzheimer’s, − and Parkinson’s disease. − The development of technologies to monitor dynamics of these neurotransmitters have largely focused on electrochemical sensing modalities, which are reliant on tethered sensing devices that adversely impact subject behavior and limit experimental paradigms. − Alternative strategies that rely on aptamer-based transistor sensors also face similar issues in addition to challenges associated with signal irreversibility, thus impeding acquisition of real-time transients. , The progression of electrochemical detection platforms supported by small, wireless device form factors seek to address these shortcomings through the elimination of tethered connections, allowing for freely moving subjects and reducing the impact on naturalistic behavior. , These devices, however, remain reliant on bulky, oversized batteries (>2 g), which impede uninterrupted operation, increases subject handling requirements, impose operational burden, and negatively impact subject social behavior . These factors are particularly limiting when correlating behavioral phenotype with biochemical measures of neural activity.…”